CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced findings from a Phase 1 study showing that allogeneic cytokine-induced ...
ST. LOUIS & SAN DIEGO--(BUSINESS WIRE)--Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results